Title:
NIRAPARIB-RESISTANT HUMAN OVARIAN CANCER CELL LINE AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/001509
Kind Code:
A1
Abstract:
Provided are a niraparib-resistant human ovarian cancer cell line and use thereof. An A2780-NiraR (CCTCC Accession NO: C202299) drug-resistant cell line is established with human ovarian cancer A2780 cell line as the parent cell by gradually increasing the concentration of PARP inhibitor niraparib from 2 μm to 40 μm. The drug resistance index of A2780-NiraR to niraparib is 8.274. In addition to the resistance to niraparib, cross-resistance to paclitaxel is also observed. The drug resistance retest of thawed cells after drug withdrawal culture for three months and liquid nitrogen cryopreservation for half a year demonstrates that the drug resistance of the A2780-NiraR cell line is greater than 90% of the original resistance, suggesting good drug resistance stability. The cell line can be used to explore tumor drug-resistant mechanisms, analyze the sensitivity to chemotherapy drugs, screen and evaluate chemotherapeutic drugs, develop drugs for reversing tumor drug resistance, study tumor treatments, and the like.
More Like This:
Inventors:
LU WEIGUO (CN)
LIN HUI (CN)
SHEN YUQING (CN)
XU JUNFEN (CN)
LIN HUI (CN)
SHEN YUQING (CN)
XU JUNFEN (CN)
Application Number:
PCT/CN2023/092013
Publication Date:
January 04, 2024
Filing Date:
May 04, 2023
Export Citation:
Assignee:
WOMENS HOSPITAL ZHEJIANG UNIV SCHOOL OF MEDICINE (CN)
International Classes:
C12N5/09; C12N5/071
Foreign References:
| CN115074311A | 2022-09-20 | |||
| CN111979290A | 2020-11-24 | |||
| CN104388389A | 2015-03-04 | |||
| CN1687405A | 2005-10-26 | |||
| JP2000253872A | 2000-09-19 | |||
| KR20210120715A | 2021-10-07 |
Attorney, Agent or Firm:
HANGZHOU QIUSHI PATENT OFFICE CO., LTD. (CN)
Download PDF: